Non-Small Cell Lung Cancer

Previous Page   Next Page

Trials are underway to assess benefit of veliparib combination therapies in NSCLC. A phase II study reported preliminary activity with veliparib compared with placebo in combination with carboplatin and paclitaxel as first-line treatment, although the modest difference in progression-free survival did not reach statistical significance [1]. A larger phase III trial (NCT02106546) is now underway to try to show progression-free survival benefit of first-line combination veliparib versus placebo with carboplatin and paclitaxel in a larger cohort of advanced or metastatic NSCLC patients.

Veliparib in combination with whole brain radiation therapy has also been studied in patients with brain metastases in NSCLC in a phase II trial (NCT01657799), but there was no significant survival improvement versus placebo [2].


  1. Ramalingam SS, Blais N, Mazieres J et al. Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 2017; 23: 1937-1944.
  2. Chabot P, Hsia TC, Ryu JS et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol 2017; 131: 105-115.
Last update: 25 July 2019